- Home
- MKC vs GMAB Comparison
MKC vs GMAB Comparison
Compare MKC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKC
- GMAB
- Stock Information
- Founded
- MKC 1889
- GMAB 1999
- Country
- MKC United States
- GMAB Denmark
- Employees
- MKC N/A
- GMAB N/A
- Industry
- MKC Packaged Foods
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MKC Consumer Staples
- GMAB Health Care
- Exchange
- MKC Nasdaq
- GMAB Nasdaq
- Market Cap
- MKC 18.3B
- GMAB 17.4B
- IPO Year
- MKC N/A
- GMAB N/A
- Fundamental
- Price
- MKC $66.90
- GMAB $31.32
- Analyst Decision
- MKC Buy
- GMAB Strong Buy
- Analyst Count
- MKC 9
- GMAB 6
- Target Price
- MKC $77.33
- GMAB $40.40
- AVG Volume (30 Days)
- MKC 2.5M
- GMAB 1.8M
- Earning Date
- MKC 10-07-2025
- GMAB 11-06-2025
- Dividend Yield
- MKC 2.86%
- GMAB N/A
- EPS Growth
- MKC N/A
- GMAB 132.41
- EPS
- MKC 2.88
- GMAB 25.10
- Revenue
- MKC $6,787,900,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- MKC $2.64
- GMAB $24.92
- Revenue Next Year
- MKC $6.07
- GMAB $15.97
- P/E Ratio
- MKC $23.32
- GMAB $1.25
- Revenue Growth
- MKC 1.64
- GMAB 29.57
- 52 Week Low
- MKC $63.15
- GMAB $17.24
- 52 Week High
- MKC $86.24
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- MKC 54.86
- GMAB 63.22
- Support Level
- MKC $64.15
- GMAB $29.98
- Resistance Level
- MKC $68.88
- GMAB $30.82
- Average True Range (ATR)
- MKC 1.33
- GMAB 0.65
- MACD
- MKC 0.34
- GMAB 0.15
- Stochastic Oscillator
- MKC 66.45
- GMAB 94.93
About MKC McCormick & Company Incorporated
In its 135-year history, McCormick has become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond consumers, McCormick's customer base includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers. And its reach is extensive, with nearly 40% of sales generated beyond its home turf to 150 countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula, among others.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.